Attachment formatting requirements for NIH are very specific. Failure to adhere to these requirements could result in application errors when submitting or withdrawing your application from funding consideration.

This topic discusses delegating authority directly to another user or to someone who needs to access your own account information. See Delegate on Behalf of Another User for delegating authority to a user on behalf of someone else. Not all roles can delegate all authorities; refer to the table in the Delegations topic for role-based constraints on delegation.

A grant number provides unique identification for the grant. This page provides a comprehensive explanation of all the components of a complete NIH grant number.

This Notice supersedes NOT-OD-24-104 and establishes stipend levels for fiscal year 2025 Kirschstein-NRSA awards for undergraduate, predoctoral, and postdoctoral trainees and fellows. Retroactive adjustments or supplementation of stipends or other budgetary categories with Kirschstein-NRSA funds for an award made prior to October 1, 2024 are not permitted.

At the end of the current application cycle (May 24, 2025), the listed NOFOs will expire with this notice. No applications due on or after May 25, 2025 will be accepted.

Effective May 1, 2025, and until the details of the new foreign collaboration award structure are released, NIH will not issue awards to domestic or foreign entities (new, renewal or non-competing continuation), that include a subaward to a foreign entity. Prior approval requests to add a new foreign component or subaward to an ongoing project will no longer be accepted by NIH.

This notice is an reminder of the longstanding requirements for projects that involve activities outside the United States or partnerships with international collaborators.

The extramural community is being informed by this notice that NIH has temporarily disabled the No-Cost Extension functionality in eRA Commons. At this time, all requests for NCEs must be submitted as a prior approval request in eRA Commons, for review and approval by the NIH. Requests for activities that do not align with the mission and priorities of the NIH will not be approved.

An automatic extension of Early-Stage Investigator (ESI) eligibility is granted by the National Institutes of Health (NIH) through this Notice. This extension aims to address any delays in grant application submissions, peer review, or award processing timelines between January 1, 2025, and May 31, 2025, and seeks to mitigate their impact on the biomedical research community.

This notification is intended to inform the biomedical research community about the immediate actions that NIH is taking in response to the Executive Order issued on May 5, 2025 to enhance the safety and security of biological research.

This notice provides information about the salary limitation for NIH grant and cooperative agreement awards, as well as extramural research and development contract awards. The salary levels of the Executive Pay Scale have been updated recently by the Office of Personnel Management. Effective January 1, 2025, the salary cap for Executive Level II has been set at $225,700.

The purpose of this notice is to inform active Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) recipients of a change in Post-Award Reporting requirements has been implemented for active awards that did not undergo foreign risk assessment at the time of their original application submission.

This serves as notification of a modification to NIH’s due diligence program to assess security risks and denial of award when foreign relationships or commitments with countries of concern pose a significant risk as provided in the SBIR and STTR Extension Act of 2022 under these programs.

In line with recent security directives, NIH is implementing a technical update to enhance security measures that are specifically designed to protect data provided by NIH Controlled-Access Data Repositories.

This Notice alerts the extramural research community of a new Civil Rights term and condition that modifies the current terms and conditions for all NIH grants, cooperative agreements, and other transaction (OT) awards. This term applies prospectively to new, renewal, supplement, or continuation awards issued on or after the date of this Notice.

The Rare Cancers Research Program (RCRP) released program announcements for the following funding opportunities:

·       Concept Award

·       Idea Development Award

·       Resource and Community Development Award

To view the program announcements and submit a pre-application visit: 

https://ebrap.org/eBRAP/public/ProgramFY.htm?programYId=665103

The Breast Cancer Research Program (BCRP) released program announcements for the following funding opportunities:

·        Breakthrough Award Levels 1 and 2

·        Breakthrough Award Level 3

·        Clinical Research Extension Award

·        Era of Hope Scholar Award

To view the program announcements and submit a pre-application visit: 

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=663101

The Ovarian Cancer Research Program (OCRP) released program announcements for the following funding opportunities:

·        Investigator-Initiated Research Award

·        Ovarian Cancer Academy - Early-Career Investigator Award

·        Pilot Award

To view the program announcements and submit a pre-application visit: 

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=663103

The Peer Reviewed Medical Research Program (PRMRP) released program announcements for the following funding opportunities:

·       Technology/Therapeutic Development Award

·       Clinical Trial Award

To view the program announcements and submit a pre-application visit: https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=671101

The Duchenne Muscular Dystrophy Research Program (DMDRP) released program announcements for the following funding opportunities:

·       Idea Development Award

·       Clinical/Translational Research Award

To view the program announcements and submit a pre-application visit https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=667101

The Amyotrophic Lateral Sclerosis Research Program (ALSRP) released program announcements for the following funding opportunities:

·        Pilot Clinical Trial Award 

·        Clinical Outcomes and Biomarkers Award

·        Therapeutic Development Award

·        Therapeutic Idea Award

To view the program announcements and submit a pre-application visit: 

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=663102

The Alzheimer’s Research Program (AZRP) released program announcements for the following funding opportunities:

·        Transforming Care Award

·        Transforming Diagnosis Award

·        Transforming Research Award

To view the program announcements and submit a pre-application visit:  

https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=663104

A. The Melanoma Research Program (MRP) re-released a pre-announcement for the following anticipated funding opportunities:

·        Survivorship Research Award

·        Focused Program Award – Rare Melanomas

·        Melanoma Academy Leadership Award **Returning for FY25**

·        Idea Award

·        Melanoma Academy Scholar Award

·        Team Science Award

To view the MRP pre-announcement, visit https://cdmrp.health.mil/pubs/press/2025/25mrppreann

B. The Prostate Cancer Research Program (PCRP) released a pre-announcement for the following funding opportunities:

·        Clinical Consortium Award **Returning for FY25**

·        Idea Development Award

To view the pre-announcement, visit https://cdmrp.health.mil/pubs/press/2025/25pcrppreann

C. The Rare Cancers Research Program (RCRP) re-released a pre-announcement for the following funding opportunities:

·        Concept Award 

·        Idea Development Award

·        Resource and Community Development Award

To view the pre-announcement, visit https://cdmrp.health.mil/pubs/press/2025/25rcrppreann

D. The Peer Reviewed Cancer Research Program (PRCRP) released a pre-announcement for the following anticipated funding opportunities:

·        Career Development Award- Fellow and Resident Option

·        Career Development Award- Scholar Option

·        Idea Award

·        Impact Award- Partnering PI Option

·        Patient Well-Being and Survivorship Award

·        Clinical Trial Award

To view the pre-announcement, visit https://cdmrp.health.mil/pubs/press/2025/25prcrppreann

Due: June 4, 2025, @ 3pm

Amount: $200,000/1 year

To pave a future where health is no longer a privilege, but a right, RWJF is focusing on dismantling structural racism, one of the biggest barriers to health in America. Effective solutions require medical care organizations working with public health and social services systems. This grant will provide funding for a new cohort of community-led pilot studies to produce new, actionable evidence about how to help medical, social, and public health systems work together to address forms of systemic racism. The focus is specifically on systems alignment (SA) interventions that have the potential to dismantle or disrupt the health effects of systemic racism and to positively affect the health and wellbeing of communities that experience systemic racism. S4A prioritizes SA interventions that, if successful, can be rapidly replicated and spread to many communities and contexts across the U.S. in order to achieve broad national impact.

Link: Systems 4 Action RFP

Please contact the Institutional Giving team at institutionalgiving@montefiore.org for further details.

Due: June 4, 2025

Amount: $100,000/2 years

Opportunity to compete for acceleration funds up to $300,000. The Scholar Award

recognizes outstanding physician-scientists whose work has the potential to advance the standard of care. The selection committee seeks breakthrough discoveries defined by innovation, creativity and potential for clinical impact, including deemed to address unmet medical needs; modulators of novel targets; potential to be developed into a commercial program; strong intellectual property (IP) or protection strategy; may be a small molecule, biologic, or other therapeutic modality; or diagnostics or devices only acceptable as part of a therapeutic development project.

Eligibility: MD, MD/PhD, or equivalent.

Link: Scholar-Innovator Award

Please contact the Institutional Giving team at institutionalgiving@montefiore.org for further details.

The Lipedema Foundation is currently accepting proposals for its 2025 Research Funding Program, supporting projects that advance understanding, diagnosis, and treatment of lipedema and related fat disorders. Investigators from a range of disciplines—including but not limited to basic science, clinical research, and translational studies—are encouraged to apply.



Final LOI Submission: June 10, 2025; 11:59 PM EST.

• Collaborative Research Award - Up to $250,000 over two years.
• Proof of Concept Award - Up to $125,000 for one year.
• Mentored Award - Up to $100,000 for two years. During the second year, applicants may apply for a third year of funding as a renewal.

This funding opportunity may be of particular interest to researchers in obesity and metabolism, adipose tissue biology, women’s health, pain and inflammation, vascular and lymphatic disorders, genetics, rehabilitation sciences, and health disparities

More information and RFP details: https://www.lipedema.org/rfp2025

NBME is excited to share that applications are open for two grant programs for medical educators and researchers looking to advance innovations in assessment. We greatly appreciate your interest in our grant programs and would like to ask for your support in sharing this opportunity with your networks.

2025 Emerging Innovators Grants

Apply by June 16, 2025

Designed for early- and mid-career faculty, researchers, and program leaders, this grant supports visionary ideas that promote equitable assessment in medical education. Up to $25,000 will be awarded for each accepted proposal. Learn more on NBME's Emerging Innovators Grants page.

2026 Stemmler Grants

Apply by June 30, 2025

Targeting mid- and senior-career researchers, this grant supports innovative assessment techniques in medical education or practice. Up to $150,000 will be awarded for each research team. Learn more on NBME’s Stemmler Grant page.

Due: July 1, 2025, 4pm

Amount: $400,000/2 years

The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with “high-risk/high-reward” ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis, or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. Applications will be accepted from all scientific disciplines provided that the proposed research meets the selection criteria.

Eligibility: The applicant must have received an MD, DO, PhD, or MD/PhD degree. Tenure-track Assistant Professors within the first five (5) years of obtaining their initial Assistant Professor position (Cut-off date: July 1, 2020). Clinical Instructors

and Senior Clinical Fellows (in the final year of sub-specialty training) holding an MD, MD/PhD, DO who are pursuing a period of independent research before taking a tenure-track faculty position. Such individuals must have an exceptional record of research accomplishment, dedicated laboratory space and the support of their institution. Applicants with a background in multiple disciplines are especially encouraged to apply.

Link: Damon Runyon-Rachleff Innovation Award

Please contact the Institutional Giving team at institutionalgiving@montefiore.org for further details.

This program has been established to promote, nurture and amplify scientific discovery and innovation in Western New York and the region. The WNYBC Discovery and Innovation Award will support basic, translational, and/or clinical research projects that will improve health outcomes, health equity, and/or preventing complications of hemophilia and/or hemostatic or thrombotic disorders.

We invite proposals from higher education institutions and non-profit organizations that have a history and track record of serving the community of bleeding and clotting disorders. There is no age requirement, however, applicant must have an MD, PhD or equivalent; clearly state they have both independent research projects and independent resources; and have preliminary results/and or publications from their independent laboratory.

Budget must not exceed $150,000/year, for up to three years. Up to two grants will be awarded annually.

APPLICATION DUE DATE July 1, 2025

GRANT START DATE  January 1, 2026

Attached please find the 2025 Grant RFP. 

QUESTIONS? Check the attached FAQs first.  

More Questions?

Contact the Grant and Award Administrator at mwiseman@wnybloodcare.org

Due: August 15, 2025

• Amount: $100,000/1 year or $200,000/2 years

• Priority is given to projects focused on studying or correcting the heterozygous effect of non-UBE3A genes in deletion, the potential results of increasing UBE3A after therapies or for some subtypes of AS, projects studying delivery of therapies and potential for improvement, and symptomatic therapies that impact the daily life of people with Angelman syndrome and their families. Proposals that do not address these topics are still welcome and will be given full consideration.

• Link: Angelman RFP

Please contact the Institutional Giving team at institutionalgiving@montefiore.org for further details.

The W.M. Keck Foundation is offering research grants up to $1.3M over three years. The first step is for Einstein to submit to the foundation up to four concept papers each in Medical Research and Science & Engineering.

If you are interested in applying, please email your c.v., including bibliography; other support(on a separate page); plus a one-page concept paper following the *outline below to Audrey McInerney (amcinerney@montefiore.org) by May 30 at 5:00 pm.

Please indicate whether your concept paper will compete in the Medical Research or Science & Engineering pool.

From among the internal concept papers, the Einstein awards committee will select up to four candidates in each of the two categories, for a total of up to eight concept candidates. Einstein’s institutional liaison will then submit the nominated concept papers to the Foundation for a preliminary review on June 23, 2025. Following this review, one selected applicant in each category will be invited to submit a Phase I application by November 1, 2025.



The Keck Foundation funds high-risk/high-impact projects that are distinctive and novel in their approach, question the prevailing paradigm, or have the potential to break open new territory in their field. They prioritize grants that pioneer biological and physical science research and engineering, including the development of promising new technologies, instrumentation, or methodologies. Future clinical applications are seen as a plus, but translational research is not their focus. Please note: The Keck Foundation defines medical research as “a focus on the human body and mammalian experimentation” and they seek a basic science impact in both medical research and science & engineering applications.

Eligibility: Senior, mid-career, and early-stage faculty (assistant professors and above) can apply.  If you are unsure about your eligibility, please contact your department administrator or Audrey McInerney (amcinerney@montefiore.org) for assistance.

Important: Please review the Keck Foundation’s Funding Guidelines to see what kinds of projects the foundation will and will not fund (scroll down).

*Outline for one-page concept paper submissions to Einstein Awards Committee

12-point font with 1-inch margins and MUST include: 

• Organization Name 
• Project Title 
• Full name of Principal Investigator 
• An overview of the proposed project emphasizing any unique aspects and pilot studies (indicate area of emphasis for project – Medical Research or Science & Engineering Research) 
• A description of the methodologies and key personnel 
• A brief justification of the need for Keck Foundation support. (Applicants need to demonstrate why private philanthropy generally, and the Keck Foundation in particular, is essential to the project’s success. The foundation advises applicants to insert quotes received from public funding agencies feedback as to why their project did not get funded, e.g., “high-quality but too risky”). 
• An estimated budget broken down, if possible, by major areas, e.g., personnel, equipment, consumable supplies, etc. 
• With any remaining space within the 1-page limit, authors may add other details 
• If a reference is necessary, abbreviate it as (Science, 323, 45, ‘11). DO NOT USE (Jones et al., 2011). Please avoid any illustrations.   

Please find additional information about the Keck Foundation’s Research Program here. And visit the Foundation's Grant Abstracts Webpage to view recently funded research projects and award amounts. Please note: If your project is similar to a recent award, the Keck board will not be interested.

If you have any questions, please contact amcinerney@montefiore.org (Institutional Liaison).

The American Diabetes Foundation is offering two limited submission research grants. If you would like to apply, please email the attached candidate profile form, your c.v., including bibliography; other support(on a separate page); plus a one-page research overview to Audrey McInerney (amcinerney@montefiore.org) by June 6 at 5:00 pm.

Also attached is a form you can use for your one-page overview.

American Diabetes Association

Pathway to Stop Diabetes 2025

• Internal Deadline: June 6, 2025
• Sponsor Deadline for Nominated PIs: July 23, 2025
• Amount: Varies by award type. Up to $1,625,000 over 5-7 years
• Einstein may nominate two proposals: one clinical (which may “span clinical through public health research”) and one in basic science (which may “span basic through preclinical research”). Potential PIs should indicate which program they are applying under: INI or ACE. See eligibility notes for each program below.
• Notes: Pathway provides crucial support to individuals focusing on innovative ideas and transformational approaches that will lead to ground-breaking discoveries in diabetes prevention, management, and cures. This call for nominations will prioritize translational applications that move knowledge and discovery gained from basic research to its eventual translation into patient and population benefit. The ideal applicant will propose innovative research that will be an important step towards the eventual goal of improving the lives of people at risk of diabetes or living with the disease - and the pathway to this impact is clear. Nominations are welcomed from all areas of diabetes and span prevention, management, and cure of all diabetes types (i.e. type 1, type 2 and gestational), diabetes-related disease states (obesity, prediabetes, and other insulin resistant states) and complications. Competitive applicants will demonstrate innovation, strong potential impact for understanding/treatment of diabetes, and a proven ability to establish an independent research program. Principal Investigator must agree to devote at least 75% of their total time and overall effort towards research. This percentage includes time dedicated to the Association-funded grant in addition to grants supported by other funding agencies.
• There are two award levels: INI for post-doctoral or research fellows, and ACE for early career faculty.

Initiator Award (INI)

• Amount: Up to $1,625,000 over 7 years
• Eligibility: Eligible applicants must currently be in research training positions (post-doctoral fellow, research fellowship) and have no more than seven years of research training following terminal doctoral degree. Applicants cannot concurrently hold an NIH K99/R00 grant. Candidates must be identified through institutional nomination; applications will be accepted only from individuals with the appropriate institution support. Applicant must be authorized to work in U.S. or U.S. possessions.
• Link: Current Funding Opportunities—Pathway to Stop Diabetes | American Diabetes Association

Accelerator Award (ACE)

• Amount: Up to $1,625,000 over 5 years
• Eligibility: Awards are available to early-career diabetes investigators proposing innovative and ambitious diabetes-related research programs. Applicants must hold faculty positions and have demonstrated independent productivity in diabetes research. Applicants may currently hold independent NIH funding (K, U or R awards, including an initial R01/U01) but must not have applied for (regardless of outcome), or received, an R01/U01 renewal or a second R01/U01 award. Applicant must be authorized to work in U.S. or U.S. possessions.
• Link: Current Funding Opportunities—Pathway to Stop Diabetes | American Diabetes Association

If you have any questions, please contact amcinerney@montefiore.org  (Institutional Liaison).